Randomized Controlled Trials (RCTs) and Real-world Outcomes in Hematological Malignancies: Minding the Gap
Blog
Read More
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Literature
Read More
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
Press Release
Read More
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Literature
Read More
ConcertAI & NeoGenomics Announce Collaboration to Advance Population-Scale, Definitive Hematological Research & Generative AI Solutions at 2024 JP Morgan Conference
Press Release
Read More
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Press Release
Read More